Crinetics

Crinetics discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of cancer and endocrine-related diseases. Read more

Scott R. Struthers's photo - Founder & CEO of Crinetics

Founder & CEO

Scott R. Struthers

CEO Approval Rating

89/100

Founded:

2008

Status:

PublicIndependent CompanyNASDAQCRNX

CRINETICS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

NexImmune is Crinetics's #1 rival. NexImmune was founded in 2011 in Gaithersburg, Maryland. Like Crinetics, NexImmune also operates in the Biotechnology space. NexImmune generates $ less revenue than Crinetics.

BMS is one of Crinetics's top competitors. BMS is headquartered in New York, New York, and was founded in 1858. Like Crinetics, BMS also works within the Biotechnology sector. BMS generates 60,295,774% the revenue of Crinetics.

Novartis is seen as one of Crinetics's top competitors. Novartis was founded in 1996, and its headquarters is in Basel, Basel-City. Novartis is in the Pharmaceuticals field. Novartis has 109,953 more employees than Crinetics.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Juno Therapeutics a competitor of Crinetics?

Crinetics Quarterly and Annual Revenue

Coming soon for Crinetics!

Annual Revenue

$ < 1M

Crinetics's revenue is the ranked lowest among it's top 10 competitors. The top 10 competitors average 10.8B.

Crinetics Acquisitions

No recent acquisitions found related to Crinetics

Crinetics Funding History

Since Crinetics was founded in 2008, it has participated in 4 rounds of funding. In total Crinetics has raised $181.5M. Crinetics' last funding round was on Jul 2018 for a total of $102.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Jul 2018
$102M
-
Series B
Feb 2018
$60M
Series A
Oct 2015
$18M
Grant
Jan 2015
$1.5M
-

Since Crinetics was founded in 2008, it has participated in 4 rounds of funding. In total Crinetics has raised $181.5M. Crinetics' last funding round was on Jul 2018 for a total of $102.0M

Crinetics Investments

No recent investments found related to Crinetics

Crinetics News

March 30, 2021MarketScreener

2021 Clinical Plans, 4th Quarter, and 2020 Financial Results

(marketscreener.com) Advancing paltusotine into a Phase 3 program for acromegaly following an FDA mee... See more »
March 24, 2021MarketScreener

4QYE 2020 Financial Results Conference Call and Webcast

(marketscreener.com) Crinetics will host a webcast and conference call to discuss its 2021 clinical p... See more »
March 22, 2021MarketScreener

Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021

(marketscreener.com) SAN DIEGO, March 22, 2021 -- Crinetics Pharmaceuticals, Inc. , a clinical stage ... See more »
March 18, 2021News Break

ProShare Advisors LLC Makes New Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) | News Break

ProShare Advisors LLC bought a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) in the four... See more »
March 12, 2021MarketScreener

ENDO 2021 Presentations Showcase Three Clinical Programs

(marketscreener.com) - Details of New Paltusotine Tablet Formulation to be Unveiled - Preclinical Evi... See more »

Crinetics Press Releases

May 13, 2019GlobeNewswire

Crinetics Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update

SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinica... See more »
March 13, 2019GlobeNewswire

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

SAN DIEGO, March 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clini... See more »
January 2, 2019GlobalNewswire

Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinic... See more »
November 20, 2018GlobeNewswire

Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference

SAN DIEGO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinic... See more »
November 13, 2018StreetInsider

Crinetics Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on th... See more »
January 4, 2018EconoTimes

Crinetics Pharmaceuticals Appoints Marc Wilson as Chief Financial Officer

Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders a... See more »

Social Media

Crinetics Headquarters

10222 Barnes Canyon Road Building 2

San Diego, California92121

1-858-450-6464

Driving Directions »

Trending Companies

Crinetics Summary

ABOUT

Overview

Crinetics discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of cancer and endocrine-related diseases. Crinetics was founded in 2008. Crinetics' headquarters is located in San Diego, California, USA 92121. ...

CEO

Crinetics's Founder & CEO, Scott R. Struthers, currently has an approval rating of 89%. Crinetics's primary competitors are NexImmune, BMS & Novartis.

Frequently Asked Questions about Crinetics

  1. When was Crinetics founded?

    Crinetics was founded in 2008
  2. Who is Crinetics's CEO?

    Crinetics's CEO is Scott R. Struthers
  3. How much revenue does Crinetics generate?

    Crinetics generates $ < 1M in revenue
  4. How much funding does Crinetics have?

    Crinetics has historically raised $181.5M in funding
  1. Where is Crinetics's headquarters?

    Crinetics's headquarters is in San Diego California, USA
  2. How many employees does Crinetics have?

    Crinetics has 47 employees
  3. What sector does Crinetics operate in?

    Crinetics is in Biotechnology
  4. Who are Crinetics's competitors?

    Crinetics's top competitors are NexImmune, BMS, Novartis